EU/3/19/2167

Table of contents

About

On 29 May 2019, orphan designation (EU/3/19/2167) was granted by the European Commission to BeiGene Ireland Limited, Ireland, for zanubrutinib, also known as (BGB-3111), for the treatment of lymphoplasmatic lymphoma.

Key facts

Active substance
Zanubrutinib
Disease / condition
Treatment of lymphoplasmacytic lymphoma
Date of first decision
29/05/2019
Outcome
Positive
EU designation number
EU/3/19/2167

Sponsor's contact details

BeiGene Ireland Limited
10 Earlsfort Terrace
Dublin 2 
D02 T380
Ireland
Tel. +353 5667 660
E-mail: bg.ireland@beigene.com
 

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-govegovernmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating